The Effect of Nano-curcumin Supplementation in Acute Pancreatitis
Status:
Not yet recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
This study aimed to investigate the effect of Nano-curcumin supplementation on clinical
symptoms and signs, length of hospital stay and inflammation level in moderate acute
pancreatitis. 42 eligible patients with moderate acute pancreatitis will randomly assign to
consume two soft gels each containing 40 mg of Nano-curcumin or placebo (control group) every
morning and evening for two weeks. Both groups will also receive the standard medical
treatment in hospital. Patients' blood samples will be taken before and after the
intervention to determine complete blood count (CBC), kidney and liver function, blood sugar,
electrolytes and C-reactive protein (CRP). Clinical signs during the hospitalization period
will be recorded and the two groups will also be compared in terms of local complications and
length of hospital stay.